Fosun Pharma (600196.SH): Englegliptin Metformin Extended-Release Tablets (III) Approved for Registration

Zhitong Finance APP news, Fosun Pharma (600196.SH) announced that its holding subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. has recently received approval from the National Medical Products Administration for the drug registration application of Ertugliflozin Metformin Extended-release Tablets (III). This approval is indicated for use in conjunction with diet control and exercise for adult patients with type 2 diabetes currently receiving treatment with Ertugliflozin and Metformin Hydrochloride, aimed at improving blood sugar control in these patients.